Cancer mouse rights sale agreed: US firm is first to exploit controversial invention
Moves to patent the controversial animal as an 'invention' sparked a wave of protest across Europe last year by groups outraged at the prospect that Harvard University, its developers, could make money from the animal's designer cancers.
However, Merck is the first major company to show any interest in exploiting the so- called 'OncoMouse' in the five years since it went on sale in the US. The European Patent Office has yet to decide whether it can be classed as a patentable invention.
The Merck deal is a relief for Du Pont, the chemicals giant behind the OncoMouse, which has invested between pounds 6m and pounds 10m over 10 years in the project. It had hoped this and similar mouse models would open up potentially lucrative drugs markets, and help scientists studying conditions ranging from heart disease to Aids. In practice, it has become an embarrassment.
Public revulsion at the concept of an animal engineered to develop cancer, coupled with unease at attempts to patent the animal, have prompted even senior figures within the industry to brand the mouse a public-relations disaster.
Du Pont claims that the OncoMouse is useful in studies of breast, colon, prostate and lung cancer. Merck has not disclosed how much it paid Du Pont, nor the lines of research that it intends to pursue. Opponents argue that, increasingly, scientists are conducting cancer research using cells cultured in the laboratory, and that to promote animal research is a retrograde step.
The European Patent Office (EPO) is trying to decide whether a patent on the animal - granted to Harvard University in 1988 - should be revoked in Europe as 'contrary to morality'. The patent, the first granted on an animal, was given a provisional go-ahead by the EPO in 1991. This provoked objections on moral, technical and legal grounds.
Inquiries by the Independent have established that the EPO has granted Harvard a third extension - to 15 April - to respond to these objections.
The EPO allowed the controversial mouse patent after deciding its potential benefit to humanity outweighed the suffering the extra genes might cause the engineered mice. But Peter Stevenson, political and legal director of Compassion in World Farming, said: 'Our opposition argued that the benefit to humanity had been given too much weight, and the fact that it has taken so long for anyone to come forward to use the technology indicates its limited use.'
He added: 'This is a test case. If we allow genetic engineering and patenting of animals to go ahead, we are giving our blessing to a whole new episode in humanity's exploitation of animals.'
- 2 Italian police 'reveal' what Jesus looked like as a young boy
- 3 General Election 2015: 14-year-old boy asks Nick Clegg – 'can you kill Katie Hopkins?'
- 4 University student in court for allegedly covering housemates' food in window cleaner and spit
- 5 Ryan Gosling posts tribute to 'Ryan Gosling Won't Eat His Cereal' creator Ryan McHenry
Italian police 'reveal' what Jesus looked like as a young boy
Who should I vote for? The Independent quiz matches best political party for undecided voters ahead of the general election
Mysterious 'X-Files' sounds heard miles above the Earth
Garland shooting: Isis claims attack on Prophet Mohamed cartoon contest in Texas as its first action on US soil
Met Gala 2015: Beyoncé manages to out-skimp Rihanna, Miley and Kim Kardashian combined with near-naked ensemble
In defence of liberal democracy
Over 50,000 families shipped out of London boroughs in the past three years due to welfare cuts and soaring rents
EU asylum policy is 'a direct threat to our civilisation', says Nigel Farage
The Rothschild Libel: Why has it taken 200 years for an anti-Semitic slur that emerged from the Battle of Waterloo to be dismissed?
General Election 2015: UK will be 'run for the wealthy and powerful' if Tories retain power, Labour warns
General election live: SNP suspends two members for disrupting Labour rally
£13676.46 - £16411.61 per annum + OTE: SThree: SThree Trainee Recruitment Cons...
£18000 - £22000 per annum + training: Ashdown Group: Business and Marketing Gr...
£20000 - £25000 per annum + Commission: SThree: Are you great at building rela...
£20000 - £22000 per annum + excellent benefits: Ashdown Group: Application Sup...